|Bid||0.00 x 1100|
|Ask||0.00 x 1000|
|Day's Range||70.71 - 70.71|
|52 Week Range||66.93 - 308.00|
|Beta (5Y Monthly)||0.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||141.15|
Subscribe to Yahoo Finance Plus to view Fair Value for TDOCLearn more
Novavax (NASDAQ: NVAX) and Teladoc Health (NYSE: TDOC) both were stock market superstars in 2020. As the pandemic deepened, investors bet on Novavax's coronavirus-vaccine program and Teladoc's ability to bring medical visits right into people's homes. As a result, Novavax shares surged 2,700% and Teladoc stock climbed 138%.
Technology stocks have continued to see heavy selling activity in 2022. Cathie Wood has been buying the dip in three names in particular.
ARK Invest CEO Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEMKT: ARKK), hit an interesting point recently. After more than doubling in 2020, the ARK Innovation ETF is now down 54% from its all-time high, while the Nasdaq is off 15% from its all-time high. What's more, the ARK Innovation ETF, as of this writing, is underperforming the Nasdaq Composite by roughly 24 percentage points over the most recent three-year period.